Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
沈阳三生制药有限责任公司 SBIO INC.
{{company.company_channel.channel_name}}
Media Room
Latest
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Follow :
X
Company Profile
Media Room
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.title}}
loading
The End
Network Errors Please Retry
{{selectname}}
{{showName}}
{{selectall}}
{{option}}
3SBio Inc. Appoints Dr. Zhenping Zhu as President of Research & Development and Chief Scientific Officer
2017-01-09 16:00
3SBio Inc. Selected as a Constituent of the MSCI China Index
2016-05-13 17:00
3SBio's PEG-irinotecan Wins IND Approval From China FDA
2016-03-07 17:24
3SBio Inc. Announces Expansion of its Leadership Team
2016-03-04 19:03
3SBio Signs Exclusive Patent License Agreement for ALT-P7, an Antibody-drug Conjugate Targeting HER2 with Alteogen
2015-10-12 08:05
3SBio Signs Exclusive Patent License Agreement for ALT-P7, an Antibody-drug Conjugate Targeting HER2 with Alteogen
2015-10-12 08:04
3SBio Inc. Selected as a Constituent of the Hang Seng Composite LargeCap & MidCap Index
2015-08-17 22:46
3SBio Acquires Zhejiang Wansheng Pharmaceutical
2015-07-24 17:07
3SBio Acquires Global Rights to Anti-TNF mAb
2015-06-22 20:55
3SBio Acquires Global Rights to Anti-TNF mAb
2015-06-22 20:55
3SBio Acquires Sirton Pharmaceuticals SpA
2015-01-26 11:13
3SBio Signs Exclusive Patent License Agreement for DIG-KT, a Bi-Specific mAb targeting VEGFR2 and Tie-2 with PharmAbcine
2015-01-15 08:00
3SBio Signs Exclusive Patent License Agreement for Tanibirumab, an Anti-VEGFR2/KDR mAb with PharmAbcine
2014-11-19 08:00
3SBio Inc. obtains exclusive licenses to develop and market JenKem's PEG-Irinotecan in China
2014-09-17 08:00
3SBio Signs Exclusive Patent License Agreement with DiNonA for Leukotuximab
2014-08-08 08:00
3SBio Inc. Exclusively Licenses Pegsiticase (Uricase PEG-20) to Selecta Biosciences to Develop Drug Candidate to Treat Gout
2014-06-18 14:22
3SBio to Develop DJ5 for Progressive Renal Failure in ADPKD Patients
2013-10-29 18:09
3SBio Inc. Announces Completion of Merger
2013-05-30 20:50
3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement
2013-05-24 13:51
3SBio Inc. Announces Extraordinary General Meeting of Shareholders
2013-05-02 13:24
1
2
3
4
5
7